What is the European Society of Cardiology (ESC) score cutoff point for determining severity in a patient with pulmonary hypertension?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

ESC Risk Stratification Cutoff Points for Pulmonary Hypertension Severity

The ESC/ERS guidelines stratify pulmonary arterial hypertension severity into three risk categories based on estimated 1-year mortality: low risk (<5% mortality), intermediate risk (5-10% mortality), and high risk (>10% mortality), using specific cutoff values across multiple clinical, functional, biochemical, imaging, and hemodynamic parameters. 1

Risk Category Definitions and Mortality Estimates

The three-tiered risk stratification system provides prognostic estimates that directly guide treatment decisions 1:

  • Low risk: Estimated 1-year mortality <5%, typically WHO functional class I-II, no progression of symptoms, no syncope, and preserved right ventricular function 1
  • Intermediate risk: Estimated 1-year mortality 5-10%, typically WHO functional class III with moderately impaired exercise capacity and signs of RV dysfunction but not RV failure 1
  • High risk: Estimated 1-year mortality >10%, typically WHO functional class III-IV with progressive disease, severe RV dysfunction or RV failure with secondary organ dysfunction 1

Specific Cutoff Values by Parameter Category

Clinical Assessment

  • WHO Functional Class: Low risk = I-II; Intermediate risk = III; High risk = IV 1
  • Syncope: Low risk = absent; Intermediate risk = occasional syncope during brisk/heavy exercise or occasional orthostatic syncope; High risk = repeated syncope with minimal activity 1
  • Right heart failure signs: Low risk = absent; Intermediate risk = absent; High risk = present 1
  • Symptom progression: Low risk = none; Intermediate risk = slow; High risk = rapid 1

Exercise Capacity

  • 6-Minute Walk Distance (6MWD): Low risk = >440 m; Intermediate risk = 165-440 m; High risk = <165 m 1, 2
  • Peak VO2 on CPET: Low risk = >15 ml/min/kg (>65% predicted); Intermediate risk = 11-15 ml/min/kg (35-65% predicted); High risk = <11 ml/min/kg (<35% predicted) 1
  • VE/VCO2 slope: Low risk = <36; Intermediate risk = 36-44.9; High risk = ≥45 1

Biochemical Markers

  • BNP levels: Low risk = <50 ng/L; Intermediate risk = 50-300 ng/L; High risk = >300 ng/L 1
  • NT-proBNP levels: Low risk = <300 ng/L; Intermediate risk = 300-1400 ng/L; High risk = >1400 ng/L 1, 2

Imaging Parameters (Echocardiography/CMR)

  • Right atrial area: Low risk = <18 cm²; Intermediate risk = 18-26 cm²; High risk = >26 cm² 1
  • Pericardial effusion: Low risk = absent; Intermediate risk = absent or minimal; High risk = present 1

Hemodynamic Parameters

  • Cardiac Index (CI): Low risk = ≥2.5 L/min/m²; Intermediate risk = 2.0-2.4 L/min/m²; High risk = <2.0 L/min/m² 1, 3
  • Right Atrial Pressure (RAP): Low risk = <8 mmHg; Intermediate risk = 8-14 mmHg; High risk = >14 mmHg 1, 3
  • Mixed Venous Oxygen Saturation (SvO2): Low risk = >65%; Intermediate risk = 60-65%; High risk = <60% 1

Application in Clinical Practice

Multiparametric Assessment Requirement

No single variable provides sufficient prognostic information; comprehensive assessment using multiple parameters is mandatory. 1 The basic evaluation should include functional class determination, at least one exercise capacity measurement (6MWD or CPET), and RV function assessment (BNP/NT-proBNP or echocardiography) 1.

Assessment Frequency

Regular follow-up assessments every 3-6 months are required in stable patients, with reassessment 3-6 months after treatment changes 1, 2.

Treatment Goals Based on Risk Status

Achievement and maintenance of low-risk status is the primary treatment goal, as this correlates with good exercise capacity, quality of life, RV function, and low mortality risk. 1, 2 Intermediate-risk status should be considered an inadequate treatment response warranting treatment escalation in most patients 1.

Critical Caveats and Limitations

Population-Specific Validation

Most cutoff values were validated primarily in idiopathic PAH populations and may not apply equally to other PAH forms (e.g., connective tissue disease-associated PAH) 1. CTD-PAH patients demonstrate higher baseline risk profiles, with 67-70% at intermediate or high risk despite background therapy 2.

Variable Discordance

Variables may fall into different risk categories for the same patient; the overall assessment pattern should guide therapeutic decisions rather than any single parameter 1. When ≥2 variables are measured, each is assigned a score of 1-3 (corresponding to low/intermediate/high risk), and the average score determines overall risk category 4.

Expert Opinion Basis

Many proposed cutoff values are based on expert opinion rather than prospective validation, requiring careful application to individual patients 1. The REVEAL 2.0 calculator demonstrates superior discrimination (c-statistic 0.73-0.76) compared to ESC/ERS-based strategies (c-statistic 0.62-0.64) in some validation studies 5.

Influence of Therapy

Approved therapies and their effects on measured variables must be considered when evaluating risk 1.

Age and Comorbidity Adjustments

Lower 6MWD values may be acceptable in elderly patients or those with comorbidities, while values >440 m may be insufficient in younger, otherwise healthy patients 1. The presence of heart or lung disease increases mortality risk even with mildly abnormal hemodynamics 6.

References

2
Guideline

Risk Stratification in CTD-PAH Patients on Selexipag

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

3
Guideline

Aviptadil Infusion Protocol for Pulmonary Arterial Hypertension

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

In a 30-year-old woman with idiopathic pulmonary arterial hypertension receiving macitentan and sildenafil, which of the following indicates a high‑risk mortality (>20% probability): cardiac index of 3.0 L/min/m², right atrial pressure of 18 mm Hg, six‑minute walk distance of 450 m, or slower onset of symptoms?
Is midodrine contraindicated in severe pulmonary hypertension?
In a newly diagnosed patient with severe pulmonary hypertension who is hemodynamically stable and breathing room air, what is the appropriate initial management?
What is the patient's cardiac risk stratification?
What is the equivalent dose of alogliptin (Dipeptidyl peptidase-4 (DPP-4) inhibitor) for a patient currently taking sitagliptin (Januvia) 100 mg for type 2 diabetes mellitus?
What are the necessary preoperative evaluations and considerations for cardiopulmonary (CP) clearance in an older adult patient with a history of cardiopulmonary issues, such as heart disease, chronic obstructive pulmonary disease (COPD), or asthma, undergoing cataract surgery?
What causes referred epigastric pain in a patient with pneumonia, particularly in those with pneumonia located at the base of the lungs?
At what size should a stable thoracic aortic aneurysm (TAA) in a female patient be intervened with surgical repair?
What is the management and treatment approach for a patient with T cell large granular lymphocytic leukemia (T-LGL), considering potential associations with autoimmune disorders or immunosuppression?
What is the recommended treatment for hypertension in African American patients, particularly those with comorbidities such as diabetes or kidney disease, using calcium channel blockers (CCBs)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.